Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Advertisement Specific types of immune cells unleashed by cancer immunotherapy appear to cause myocarditis, an ...
TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...
The heart tissue showed upregulation of molecular pathways that help recruit and retain immune cells involved in inflammation ...
News Medical on MSN7d
Virtual screening yields small molecules to enhance cancer immunotherapyThe process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine ...
The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...
Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...
This study investigated patients with primary lung cancer who received PET/CT scan, a medical imaging test, and subsequently ...
Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback